Molecular markers of prognosis and therapeutic targets in metastatic colorectal cancer

Surgical Oncology

Volumn 25, Issue 3, 2016, Pages 190-199

  Ronnekleiv Kelly, Sean M ^a   Burkhart, Richard A ^a   Pawlik, Timothy M ^a  

^a JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

Biologic therapy; Colorectal; Metastatic colorectal cancer; Molecular markers; Targeted therapy

Indexed keywords

B RAF KINASE; BEVACIZUMAB; CAPECITABINE PLUS OXALIPLATIN; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IRINOTECAN; K RAS PROTEIN; KI 67 ANTIGEN; MESSENGER RNA; MISMATCH REPAIR PROTEIN PMS2; MITOGEN ACTIVATED PROTEIN KINASE; MOLECULAR MARKER; OXALIPLATIN; PANITUMUMAB; PEMBROLIZUMAB; PROTEIN MLH1; PROTEIN MSH2; PROTEIN MSH6; PROTEIN P53; RAMUCIRUMAB; TELOMERASE; VASCULOTROPIN; PROTEIN KINASE; PROTEIN KINASE INHIBITOR; RAS PROTEIN; TUMOR MARKER;

ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; GENE MUTATION; GENETIC ASSOCIATION; GENOMIC INSTABILITY; HUMAN; LYMPHOCYTIC INFILTRATION; METASTATIC COLORECTAL CANCER; MICROSATELLITE INSTABILITY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; TUMOR MICROENVIRONMENT; CHEMISTRY; COLORECTAL NEOPLASMS; GENETICS; MUTATION; PATHOLOGY; PROGNOSIS;

BIOMARKERS, TUMOR; COLORECTAL NEOPLASMS; HUMANS; MUTATION; PROGNOSIS; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; RAS PROTEINS;

EID: 84971379045     PISSN: 09607404     EISSN: 18793320     Source Type: Journal    
DOI: 10.1016/j.suronc.2016.05.018     Document Type: Article

References (76)

1. H.J. Wanebo, M. LeGolvan, P.B. Paty, S. Saha, M. Zuber, M.I. D'Angelica, and et al. Meeting the biologic challenge of colorectal metastases Clin. Exp. Metastasis 29 7 2012 821 839
2. T.C. Chua, A. Saxena, W. Liauw, A. Kokandi, and D.L. Morris Systematic review of randomized and nonrandomized trials of the clinical response and outcomes of neoadjuvant systemic chemotherapy for resectable colorectal liver metastases Ann. Surg. Oncol. 17 2 2010 492 501
3. American Cancer Society Colorectal Cancer Facts and Figures 2014-2016 2014 American Cancer Society
4. L.C. Bredt, and A.F. Rachid Predictors of recurrence after a first hepatectomy for colorectal cancer liver metastases: a retrospective analysis World J. Surg. Oncol. 12 2014 391
5. G. Spolverato, A. Ejaz, N. Azad, and T.M. Pawlik Surgery for colorectal liver metastases: the evolution of determining prognosis World J. Gastrointest. Oncol. 5 12 2013 207 221
6. Y. Fong, J. Fortner, R.L. Sun, M.F. Brennan, and L.H. Blumgart Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases Ann. Surg. 230 3 1999 18 21 309-18; discussion
7. W.S. Chung, M.S. Park, S.J. Shin, S.E. Baek, Y.E. Kim, J.Y. Choi, and et al. Response evaluation in patients with colorectal liver metastases: RECIST version 1.1 versus modified CT criteria AJR Am. J. Roentgenol. 199 4 2012 809 815
8. D.G. Blazer 3rd, Y. Kishi, D.M. Maru, S. Kopetz, Y.S. Chun, M.J. Overman, and et al. Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases J. Clin. Oncol. 26 33 2008 5344 5351
9. B. Gruenberger, W. Scheithauer, R. Punzengruber, C. Zielinski, D. Tamandl, and T. Gruenberger Importance of response to neoadjuvant chemotherapy in potentially curable colorectal cancer liver metastases BMC Cancer 8 2008 120
10. E.A. Eisenhauer, P. Therasse, J. Bogaerts, L.H. Schwartz, D. Sargent, R. Ford, and et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur. J. Cancer 45 2 2009 228 247
11. P. Boonsirikamchai, M.A. Asran, D.M. Maru, J.N. Vauthey, H. Kaur, S. Kopetz, and et al. CT findings of response and recurrence, independent of change in tumor size, in colorectal liver metastasis treated with bevacizumab AJR Am. J. Roentgenol. 197 6 2011 W1060 W1066
12. Y.S. Chun, J.N. Vauthey, P. Boonsirikamchai, D.M. Maru, S. Kopetz, M. Palavecino, and et al. Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases JAMA 302 21 2009 2338 2344
13. L. Rubbia-Brandt, E. Giostra, C. Brezault, A.D. Roth, A. Andres, V. Audard, and et al. Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery Ann. Oncol. 18 2 2007 299 304
14. M. Schirripa, F. Bergamo, C. Cremolini, M. Casagrande, S. Lonardi, G. Aprile, and et al. BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resection Br. J. Cancer 112 12 2015 1921 1928
15. J. Goldstein, B. Tran, J. Ensor, P. Gibbs, H.L. Wong, S.F. Wong, and et al. Multicenter retrospective analysis of metastatic colorectal cancer (CRC) with high-level microsatellite instability (MSI-H) Ann. Oncol. 25 5 2014 1032 1038
16. R. Bertorelle, M. Briarava, E. Rampazzo, L. Biasini, M. Agostini, I. Maretto, and et al. Telomerase is an independent prognostic marker of overall survival in patients with colorectal cancer Br. J. Cancer 108 2 2013 278 284
17. J. Barbazan, L. Muinelo-Romay, M. Vieito, S. Candamio, A. Diaz-Lopez, A. Cano, and et al. A multimarker panel for circulating tumor cells detection predicts patient outcome and therapy response in metastatic colorectal cancer Int. J. Cancer 135 11 2014 2633 2643
18. J. Tie, I. Kinde, Y. Wang, H.L. Wong, J. Roebert, M. Christie, and et al. Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer Ann. Oncol. 26 8 2015 1715 1722
19. A. Ivanecz, R. Kavalar, M. Palfy, V. Pivec, M. Sremec, M. Horvat, and et al. Can we improve the clinical risk score? the prognostic value of p53, Ki-67 and thymidylate synthase in patients undergoing radical resection of colorectal liver metastases HPB Oxf. 16 3 2014 235 242
20. S.K. Maithel, M. Gonen, H. Ito, R.P. Dematteo, P.J. Allen, Y. Fong, and et al. Improving the clinical risk score: an analysis of molecular biomarkers in the era of modern chemotherapy for resectable hepatic colorectal cancer metastases Surgery 151 2 2012 162 170
21. C.P. Neal, G. Garcea, H. Doucas, M.M. Manson, C.D. Sutton, A.R. Dennison, and et al. Molecular prognostic markers in resectable colorectal liver metastases: a systematic review Eur. J. Cancer 42 12 2006 1728 1743
22. M. Koopman, G.A. Kortman, L. Mekenkamp, M.J. Ligtenberg, N. Hoogerbrugge, N.F. Antonini, and et al. Deficient mismatch repair system in patients with sporadic advanced colorectal cancer Br. J. Cancer 100 2 2009 266 273
23. E. Vilar, and J. Tabernero Molecular dissection of microsatellite instable colorectal cancer Cancer Discov. 3 5 2013 502 511
24. F.A. Sinicrope, N.R. Foster, S.N. Thibodeau, S. Marsoni, G. Monges, R. Labianca, and et al. DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy J. Natl. Cancer Inst. 103 11 2011 863 875
25. D.T. Le, J.N. Uram, H. Wang, B.R. Bartlett, H. Kemberling, A.D. Eyring, and et al. PD-1 blockade in tumors with mismatch-repair deficiency N. Engl. J. Med. 372 26 2015 2509 2520
26. C. Tan, and X. Du KRAS mutation testing in metastatic colorectal cancer World J. Gastroenterol. 18 37 2012 5171 5180
27. T.J. Price, M.A. Bruhn, C.K. Lee, J.E. Hardingham, A.R. Townsend, K.P. Mann, and et al. Correlation of extended RAS and PIK3CA gene mutation status with outcomes from the phase III AGITG MAX STUDY involving capecitabine alone or in combination with bevacizumab plus or minus mitomycin C in advanced colorectal cancer Br. J. Cancer 112 6 2015 963 970
28. H.I. Hurwitz, J. Yi, W. Ince, W.F. Novotny, and O. Rosen The clinical benefit of bevacizumab in metastatic colorectal cancer is independent of K-ras mutation status: analysis of a phase III study of bevacizumab with chemotherapy in previously untreated metastatic colorectal cancer Oncologist 14 1 2009 22 28
29. R. Yaeger, E. Cowell, J.F. Chou, A.N. Gewirtz, L. Borsu, E. Vakiani, and et al. RAS mutations affect pattern of metastatic spread and increase propensity for brain metastasis in colorectal cancer Cancer 121 8 2015 1195 1203
30. J.N. Vauthey, G. Zimmitti, S.E. Kopetz, J. Shindoh, S.S. Chen, A. Andreou, and et al. RAS mutation status predicts survival and patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases Ann. Surg. 258 4 2013 26 27 619-26; discussion
31. G. Karagkounis, M.S. Torbenson, H.D. Daniel, N.S. Azad, L.A. Diaz Jr., R.C. Donehower, and et al. Incidence and prognostic impact of KRAS and BRAF mutation in patients undergoing liver surgery for colorectal metastases Cancer 119 23 2013 4137 4144
32. G.A. Margonis, G. Spolverato, Y. Kim, G. Karagkounis, M.A. Choti, and T.M. Pawlik Effect of KRAS mutation on long-term outcomes of patients undergoing hepatic resection for colorectal liver metastases Ann. Surg. Oncol. 22 13 2015 4158 4165
33. G.A. Margonis, Y. Kim, G. Spolverato, A. Ejaz, R. Gupta, D. Cosgrove, and et al. Association between specific mutations in KRAS Codon 12 and colorectal liver metastasis JAMA Surg. 150 8 2015 722 729
34. H.J. Andreyev, A.R. Norman, D. Cunningham, J. Oates, B.R. Dix, B.J. Iacopetta, and et al. Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study Br. J. Cancer 85 5 2001 692 696
35. H.J. Andreyev, A.R. Norman, D. Cunningham, J.R. Oates, and P.A. Clarke Kirsten ras mutations in patients with colorectal cancer: the multicenter "RASCAL" study J. Natl. Cancer Inst. 90 9 1998 675 684
36. C. Bokemeyer, E. Van Cutsem, P. Rougier, F. Ciardiello, S. Heeger, M. Schlichting, and et al. Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials Eur. J. Cancer 48 10 2012 1466 1475
37. J. Tie, and J. Desai Targeting BRAF mutant metastatic colorectal cancer: clinical implications and emerging therapeutic strategies Target Oncol. 10 2 2015 179 188
38. B. Tran, S. Kopetz, J. Tie, P. Gibbs, Z.Q. Jiang, C.H. Lieu, and et al. Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer Cancer 117 20 2011 4623 4632
39. A.B. Benson 3rd, A.P. Venook, T. Bekaii-Saab, E. Chan, Y.J. Chen, H.S. Cooper, and et al. Colon cancer, version 3.2014 J. Natl. Compr. Canc Netw. 12 7 2014 1028 1059
40. R. Bertorelle, E. Rampazzo, S. Pucciarelli, D. Nitti, and A. De Rossi Telomeres, telomerase and colorectal cancer World J. Gastroenterol. 20 8 2014 1940 1950
41. D. Hanahan, and R.A. Weinberg Hallmarks of cancer: the next generation Cell 144 5 2011 646 674
42. L. Terrin, E. Rampazzo, S. Pucciarelli, M. Agostini, R. Bertorelle, G. Esposito, and et al. Relationship between tumor and plasma levels of hTERT mRNA in patients with colorectal cancer: implications for monitoring of neoplastic disease Clin. Cancer Res. 14 22 2008 7444 7451
43. S. Pucciarelli, E. Rampazzo, M. Briarava, I. Maretto, M. Agostini, M. Digito, and et al. Telomere-specific reverse transcriptase (hTERT) and cell-free RNA in plasma as predictors of pathologic tumor response in rectal cancer patients receiving neoadjuvant chemoradiotherapy Ann. Surg. Oncol. 19 9 2012 3089 3096
44. B. Groot Koerkamp, N.N. Rahbari, M.W. Buchler, M. Koch, and J. Weitz Circulating tumor cells and prognosis of patients with resectable colorectal liver metastases or widespread metastatic colorectal cancer: a meta-analysis Ann. Surg. Oncol. 20 7 2013 2156 2165
45. F.J. Vogelaar, W.E. Mesker, A.M. Rijken, G.W. van Pelt, A.M. van Leeuwen, H.J. Tanke, and et al. Clinical impact of different detection methods for disseminated tumor cells in bone marrow of patients undergoing surgical resection of colorectal liver metastases: a prospective follow-up study BMC Cancer 10 2010 153
46. M. Koch, P. Kienle, U. Hinz, D. Antolovic, J. Schmidt, C. Herfarth, and et al. Detection of hematogenous tumor cell dissemination predicts tumor relapse in patients undergoing surgical resection of colorectal liver metastases Ann. Surg. 241 2 2005 199 205
47. C. Bettegowda, M. Sausen, R.J. Leary, I. Kinde, Y. Wang, N. Agrawal, and et al. Detection of circulating tumor DNA in early- and late-stage human malignancies Sci. Transl. Med. 6 224 2014 224ra24
48. C.L. Vale, J.F. Tierney, D. Fisher, R.A. Adams, R. Kaplan, T.S. Maughan, and et al. Does anti-EGFR therapy improve outcome in advanced colorectal cancer? A systematic review and meta-analysis Cancer Treat. Rev. 38 6 2012 618 625
49. W. Shaib, R. Mahajan, and B. El-Rayes Markers of resistance to anti-EGFR therapy in colorectal cancer J. Gastrointest. Oncol. 4 3 2013 308 318
50. C. Bokemeyer, I. Bondarenko, A. Makhson, J.T. Hartmann, J. Aparicio, F. de Braud, and et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer J. Clin. Oncol. 27 5 2009 663 671
51. E. Van Cutsem, C.H. Kohne, E. Hitre, J. Zaluski, C.R. Chang Chien, A. Makhson, and et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer N. Engl. J. Med. 360 14 2009 1408 1417
52. E. Van Cutsem, C.H. Kohne, I. Lang, G. Folprecht, M.P. Nowacki, S. Cascinu, and et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status J. Clin. Oncol. 29 15 2011 2011 2019
53. D. Cunningham, Y. Humblet, S. Siena, D. Khayat, H. Bleiberg, A. Santoro, and et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer N. Engl. J. Med. 351 4 2004 337 345
54. H. Wilke, R. Glynne-Jones, J. Thaler, A. Adenis, P. Preusser, E.A. Aguilar, and et al. Cetuximab plus irinotecan in heavily pretreated metastatic colorectal cancer progressing on irinotecan: MABEL Study J. Clin. Oncol. 26 33 2008 5335 5343
55. E. Van Cutsem, M. Peeters, S. Siena, Y. Humblet, A. Hendlisz, B. Neyns, and et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer J. Clin. Oncol. 25 13 2007 1658 1664
56. J.Y. Douillard, S. Siena, J. Cassidy, J. Tabernero, R. Burkes, M. Barugel, and et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study J. Clin. Oncol. 28 31 2010 4697 4705
57. J.Y. Douillard, S. Siena, J. Cassidy, J. Tabernero, R. Burkes, M. Barugel, and et al. Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer Ann. Oncol. 25 7 2014 1346 1355
58. L.C. Ye, T.S. Liu, L. Ren, Y. Wei, D.X. Zhu, S.Y. Zai, and et al. Randomized controlled trial of cetuximab plus chemotherapy for patients with KRAS wild-type unresectable colorectal liver-limited metastases J. Clin. Oncol. 31 16 2013 1931 1938
59. M. Peeters, K.S. Oliner, T.J. Price, A. Cervantes, A.F. Sobrero, M. Ducreux, and et al. Analysis of KRAS/NRAS mutations in a phase III study of panitumumab with FOLFIRI compared with FOLFIRI alone as second-line treatment for metastatic colorectal Cancer Clin. Cancer Res. 21 24 2015 5469 5479
60. C. Bokemeyer, I. Bondarenko, J.T. Hartmann, F. de Braud, G. Schuch, A. Zubel, and et al. Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study Ann. Oncol. 22 7 2011 1535 1546
61. T.S. Maughan, R.A. Adams, C.G. Smith, A.M. Meade, M.T. Seymour, R.H. Wilson, and et al. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial Lancet 377 9783 2011 2103 2114
62. J. Primrose, S. Falk, M. Finch-Jones, J. Valle, D. O'Reilly, A. Siriwardena, and et al. Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial Lancet Oncol. 15 6 2014 601 611
63. C. Mao, Z.Y. Yang, X.F. Hu, Q. Chen, and J.L. Tang PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis Ann. Oncol. 23 6 2012 1518 1525
64. H. Hurwitz, L. Fehrenbacher, W. Novotny, T. Cartwright, J. Hainsworth, W. Heim, and et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N. Engl. J. Med. 350 23 2004 2335 2342
65. L.T. Macedo, A.B. da Costa Lima, and A.D. Sasse Addition of bevacizumab to first-line chemotherapy in advanced colorectal cancer: a systematic review and meta-analysis, with emphasis on chemotherapy subgroups BMC Cancer 12 2012 89
66. L.B. Saltz, S. Clarke, E. Diaz-Rubio, W. Scheithauer, A. Figer, R. Wong, and et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study J. Clin. Oncol. 26 12 2008 2013 2019
67. F. Kabbinavar, H.I. Hurwitz, L. Fehrenbacher, N.J. Meropol, W.F. Novotny, G. Lieberman, and et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer J. Clin. Oncol. 21 1 2003 60 65
68. B. Gruenberger, D. Tamandl, J. Schueller, W. Scheithauer, C. Zielinski, F. Herbst, and et al. Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer J. Clin. Oncol. 26 11 2008 1830 1835
69. E. Van Cutsem, F. Rivera, S. Berry, A. Kretzschmar, M. Michael, M. DiBartolomeo, and et al. Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study Ann. Oncol. 20 11 2009 1842 1847
70. A. Okines, O.D. Puerto, D. Cunningham, I. Chau, E. Van Cutsem, L. Saltz, and et al. Surgery with curative-intent in patients treated with first-line chemotherapy plus bevacizumab for metastatic colorectal cancer First BEAT and the randomised phase-III NO16966 trial Br. J. Cancer 101 7 2009 1033 1038
71. C.J. Allegra, G. Yothers, M.J. O'Connell, S. Sharif, N.J. Petrelli, L.H. Colangelo, and et al. Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08 J. Clin. Oncol. 29 1 2011 11 16
72. E. Van Cutsem, J. Tabernero, R. Lakomy, H. Prenen, J. Prausova, T. Macarulla, and et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen J. Clin. Oncol. 30 28 2012 3499 3506
73. J. Tabernero, T. Yoshino, A.L. Cohn, R. Obermannova, G. Bodoky, R. Garcia-Carbonero, and et al. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study Lancet Oncol. 16 5 2015 499 508
74. L.G. Ahronian, E.M. Sennott, E.M. Van Allen, N. Wagle, E.L. Kwak, J.E. Faris, and et al. Clinical acquired resistance to RAF inhibitor combinations in BRAF-mutant colorectal Cancer through MAPK pathway alterations Cancer Discov. 5 4 2015 358 367
75. R.B. Corcoran, C.E. Atreya, G.S. Falchook, E.L. Kwak, D.P. Ryan, J.C. Bendell, and et al. Combined BRAF and MEK inhibition with dabrafenib and trametinib in BRAF V600-mutant colorectal cancer J. Clin. Oncol. 1 33 2015 4023 4031
76. J.C.A.C. Bendell, T. Andre, J. Tabernero, M.S. Gordon, R. Bernards, E. Van Cutsem, S. Tejpar, R. Sidhu, W.Y. Go, A. Allred, M. Motwani, B.B. Suttle, Y. Wu, A. Hoos, K.W. Orford, R.B. Corcoran, and J.H.M. Schellens Efficacy and tolerability in an open-label phas I/II study of MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D) and anti-EGFR antibody panitumumab (P) in combination in patients with BRAF V600E mutated colorectal cancer (CRC) J. Clin. Oncol. 5s 2014 32